Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 637 of 5804
-
Promising combo aims to shrink esophageal tumors before surgery
Disease control OngoingChina with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squ…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can a daily pill bring back skin color? new trial tests ritlecitinib for vitiligo
Disease control CompletedA 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cocktail of drugs aims to tackle multiple myeloma early
Disease control Recruiting nowA Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-…
Phase: PHASE2 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Brain radiation boost may extend cancer control in lung and melanoma patients
Disease control Recruiting nowThe primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymp…
Phase: PHASE3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal c…
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of SKB264 monotherapy in subjects with selected advanced solid tumors.The study is divided into two parts: the Part Ⅰ consists of 5 cohorts, and the Part Ⅱ for expansion. Eligible subjects will receive SKB264 monother…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Veterans' suicide study tests new talk therapy
Disease control OngoingThe purpose of this project is to conduct a randomized control trial with 470 Veterans to examine the impact of a revised version of Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) on risk for suicide attempts and suicidal ideation when compared to high quality u…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug eplontersen tested for Long-Term safety in heart disease patients
Disease control ENROLLING_BY_INVITATIONThe purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gut bacteria may boost lung cancer therapy
Disease control Recruiting nowThis is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcin…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 26, 2026 16:52 UTC
-
Brain tumor patients get Virus-Radiation combo in early trial
Disease control Recruiting nowThe primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
Phase: PHASE1 • Sponsor: Henry Ford Health System • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Diabetes drug metformin tested as new weapon against kidney disease
Disease control Recruiting nowThis study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function decline, reducing morbidity and mortality and improving th…
Phase: PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a cancer drug help kids with rare brain disorder?
Disease control Recruiting nowThis study is a two periods multi-center Phase II trial, with a 6 months double-blind, placebo-controlled period followed by open label period, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polym…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to cut transfusions and boost brain health in premature infants
Disease control Recruiting nowIn this phase II trial, the investigators overarching goal is to demonstrate the feasibility and potential benefit of darbepoetin (Darbe) plus slow-release intravenous (IV) iron to decrease transfusions, maintain iron sufficiency and improve the neurodevelopmental outcomes of pre…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for aggressive lymphoma: targeted drug combo enters trial
Disease control Recruiting nowThis study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Phase: PHASE2 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Triple threat: new combo targets nasopharyngeal cancer spread
Disease control OngoingThis is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could your own immune cells fight brain tumors? new trial tests lifileucel
Disease control OngoingThis is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 16:19 UTC
-
New hope for patients with rare brain lining cancer spread
Disease control OngoingThe objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma…
Phase: PHASE1 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis clinical trial aims to evaluate the safety, immunogenicity, and preliminary efficacy of a personalized neoantigen peptide vaccine in patients with advanced cancer or at high risk of recurrence. The study is designed for patients whose tumors have specific mutations identifia…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Fast-MRI could spot liver cancer earlier than ultrasound alone
Diagnosis Recruiting nowIntro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year. The latter occur in 85% of cases in cirrhosis, the most frequent causes of which are excessive alcohol consumption, metabolic syndro…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control CompletedTo evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Phase: PHASE3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC